Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1998 Sep;53(9):732–737. doi: 10.1136/thx.53.9.732

Long term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

M Ballmann 1, P Rabsch 1, H von der Hardt 1
PMCID: PMC1745320  PMID: 10319054

Abstract

BACKGROUND—Colonisation with Pseudomonas aeruginosa (PA) is a striking feature of lung involvement in cystic fibrosis. To identify the clinical consequences of the different steps of colonisation with PA under a defined therapeutic regime (no prophylactic antibiotic treatment as long as patients had no severe pulmonary disease), their influence on pulmonary function and on therapeutic intensity was examined.
METHODS—Forty patients with cystic fibrosis were followed from first detection of PA (PA1), chronic PA colonisation (PAc), first mucoid PA detection (PAm), to chronic mucoid PA colonisation (PAcm). Percentage predicted forced expiratory volume in one second (FEV1), the number of intravenous antibiotic treatment courses, and the percentage of patients on inhaled antibiotics were followed retrospectively and longitudinally in relation to the different steps of PA colonisation. The annual changes in FEV1 and therapeutic intensity in the two years preceding each step were compared with the two years following each step. Changes in FEV1 were related to therapeutic intensity.
RESULTS—The mean (SD) annual changes in FEV1 (% predicted) worsened significantly only with the transition to the mucoid stages (PAm: 4.6 (13.2) versus -4.3 (8.1); PAcm: 7.3 (12.0) versus -4.8 (7.4)) with a mean difference (95% CI) between before and after the transition of 8.9 (2.6 to 15.2) for PAm and 12.1 (6.4 to 17.6) for PAcm. With non-mucoid PA stages the therapeutic intensity increased in the year of transition and with mucoid PA stages it increased in the years following transition. Therapeutic intensity was unrelated to changes in FEV1.
CONCLUSION—With the treatment regime used an accelerated decrease in FEV1 was successfully prevented in the non-mucoid stages but not in the mucoid stages of PA colonisation.



Full Text

The Full Text of this article is available as a PDF (135.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Demko C. A., Byard P. J., Davis P. B. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol. 1995 Aug;48(8):1041–1049. doi: 10.1016/0895-4356(94)00230-n. [DOI] [PubMed] [Google Scholar]
  2. Frederiksen B., Koch C., Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997 May;23(5):330–335. doi: 10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  3. Frederiksen B., Lanng S., Koch C., Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol. 1996 Mar;21(3):153–158. doi: 10.1002/(SICI)1099-0496(199603)21:3<153::AID-PPUL1>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  4. GIBSON L. E., COOKE R. E. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959 Mar;23(3):545–549. [PubMed] [Google Scholar]
  5. Henry R. L., Dorman D. C., Brown J., Mellis C. Mucoid Pseudomonas aeruginosa in cystic fibrosis. Aust Paediatr J. 1982 Mar;18(1):43–45. doi: 10.1111/j.1440-1754.1982.tb01979.x. [DOI] [PubMed] [Google Scholar]
  6. Henry R. L., Mellis C. M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992 Mar;12(3):158–161. doi: 10.1002/ppul.1950120306. [DOI] [PubMed] [Google Scholar]
  7. Hodson M. E. Maintenance treatment with antibiotics in cystic fibrosis patients. Sense or nonsense? Neth J Med. 1995 Jun;46(6):288–292. doi: 10.1016/0300-2977(95)00021-e. [DOI] [PubMed] [Google Scholar]
  8. Hodson M. E., Penketh A. R., Batten J. C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981 Nov 21;2(8256):1137–1139. doi: 10.1016/s0140-6736(81)90588-2. [DOI] [PubMed] [Google Scholar]
  9. Hodson M. E., Roberts C. M., Butland R. J., Smith M. J., Batten J. C. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet. 1987 Jan 31;1(8527):235–237. doi: 10.1016/s0140-6736(87)90062-6. [DOI] [PubMed] [Google Scholar]
  10. Kerem E., Corey M., Gold R., Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr. 1990 May;116(5):714–719. doi: 10.1016/s0022-3476(05)82653-8. [DOI] [PubMed] [Google Scholar]
  11. Knudson R. J., Lebowitz M. D., Holberg C. J., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983 Jun;127(6):725–734. doi: 10.1164/arrd.1983.127.6.725. [DOI] [PubMed] [Google Scholar]
  12. Koch C., Høiby N. Pathogenesis of cystic fibrosis. Lancet. 1993 Apr 24;341(8852):1065–1069. doi: 10.1016/0140-6736(93)92422-p. [DOI] [PubMed] [Google Scholar]
  13. Kraemer R., Rüdeberg A., Kläy M., Rossi E. Relationship between clinical conditions, radiographic findings and pulmonary functions in patients with cystic fibrosis. Helv Paediatr Acta. 1979;34(5):417–428. [PubMed] [Google Scholar]
  14. Kubesch P., Dörk T., Wulbrand U., Kälin N., Neumann T., Wulf B., Geerlings H., Weissbrodt H., von der Hardt H., Tümmler B. Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis. Lancet. 1993 Jan 23;341(8839):189–193. doi: 10.1016/0140-6736(93)90062-l. [DOI] [PubMed] [Google Scholar]
  15. Lang A. B., Schaad U. B., Rüdeberg A., Wedgwood J., Que J. U., Fürer E., Cryz S. J., Jr Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr. 1995 Nov;127(5):711–717. doi: 10.1016/s0022-3476(95)70158-3. [DOI] [PubMed] [Google Scholar]
  16. MacLusky I. B., Gold R., Corey M., Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7(1):42–48. doi: 10.1002/ppul.1950070110. [DOI] [PubMed] [Google Scholar]
  17. Pedersen S. S., Høiby N., Espersen F., Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax. 1992 Jan;47(1):6–13. doi: 10.1136/thx.47.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ramsey B. W., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Kravitz R. M., Schidlow D. V., Wilmott R. W., Astley S. J., McBurnie M. A. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993 Jun 17;328(24):1740–1746. doi: 10.1056/NEJM199306173282403. [DOI] [PubMed] [Google Scholar]
  19. Ramsey B. W. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996 Jul 18;335(3):179–188. doi: 10.1056/NEJM199607183350307. [DOI] [PubMed] [Google Scholar]
  20. Regelmann W. E., Elliott G. R., Warwick W. J., Clawson C. C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):914–921. doi: 10.1164/ajrccm/141.4_Pt_1.914. [DOI] [PubMed] [Google Scholar]
  21. Steinkamp G., Tümmler B., Gappa M., Albus A., Potel J., Döring G., von der Hardt H. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol. 1989;6(2):91–98. doi: 10.1002/ppul.1950060207. [DOI] [PubMed] [Google Scholar]
  22. Stern R. C. Denmark to the rescue. Pediatr Pulmonol. 1996 Mar;21(3):151–152. doi: 10.1002/1099-0496(199603)21:3<151::aid-ppul1950210303>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  23. Szaff M., Høiby N., Flensborg E. W. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand. 1983 Sep;72(5):651–657. doi: 10.1111/j.1651-2227.1983.tb09789.x. [DOI] [PubMed] [Google Scholar]
  24. Taylor R. F., Hodson M. E. Cystic fibrosis: antibiotic prescribing practices in the United Kingdom and Eire. Respir Med. 1993 Oct;87(7):535–539. doi: 10.1016/0954-6111(93)90010-w. [DOI] [PubMed] [Google Scholar]
  25. Valerius N. H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991 Sep 21;338(8769):725–726. doi: 10.1016/0140-6736(91)91446-2. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES